AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$MGX

Wapnick Pamela sold $2K of MGX

Wapnick Pamela (Chief Financial Officer) sold 1,911 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.16 on 2026-09-08.

Original reporting
SEC EDGAR · Wapnick Pamela
Published Sep 10, 2026, 7:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MGX
Neutral
high confidence
Mentioned
$MGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGXNeutralLow
01

Why it matters

The transaction represents a routine liquidity move with negligible market impact.

02

Market read

Low relevance; small insider sale unlikely to affect trading decisions.

03

What to watch

Potential upcoming dilution or financing events not disclosed here.

Relevance 3/10Novelty 4/10Timing: filed Sep 10, 2026

Background

Form 4 filings disclose insider trades; this filing reports a modest sale by the CFO.

Company-level read

Ticker impact

$MGXNeutralHigh confidence
Context

CFO Wapnick Pamela sold 1,911 shares for $2,213.70 in an open-market transaction.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

Sale size is tiny relative to float and market cap; no immediate trading signal.

Market effects

Sector

None; isolated insider transaction.

Regional

None; limited to MGX shareholders.

Global

None

Counterpoint

What could challenge this read

If insider is reducing exposure, could signal concerns, but size is too small to act on.

Key entities

  • Company
    Metagenomi Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker MGX.

  • Person
    Wapnick Pamela

    Chief Financial Officer of Metagenomi Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MGX insider trading history →

Related articles

AUG 10
$MGXMed

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

SEC EDGAR 8-K4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min